 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Investors in Catalyst Pharmaceuticals Inc (CPRX) saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the...

First Week of May 17th Options Trading For Catalyst Pharmaceuticals (CPRX)

A month has gone by since the last earnings report for Catalyst Pharmaceutical (CPRX). Shares have lost about 0.6% in that time frame, underperforming the S&P 500.Will the recent negative trend...

Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Catalyst Pharmaceuticals announces support for inaugural LEMS awareness day

CORAL GABLES, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...

Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day

CORAL GABLES, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing...

Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium

AGAMREE is U.S. FDA approved and now available in the United States for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and olderThis follows the first commercial...

Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE  (Vamorolone) in the United States

AGAMREE (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile Available in the U.S. by Prescription for...

Catalyst Pharmaceuticals Announces AGAMREE  Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)

Catalyst Pharmaceuticals initiated with bullish view at BofA

BofA starts 'unique aggregator' Catalyst Pharmaceuticals with a Buy

This is a signal that CPRX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Catalyst Pharmaceuticals (CPRX, $16.27) RSI Indicator left the overbought zone on March 05, 2024

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Volume (M)	7.42M
52-Wk High	$17.77
52-Wk Low	$11.09

CPRX Catalyst Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals